Bicycle Therapeutics PLC ADR BCYC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCYC is a good fit for your portfolio.
News
-
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
-
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
-
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
-
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
-
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Bicycle Therapeutics Shares Rise 8% After Continuation of BT8009 Development
Trading Information
- Previous Close Price
- $22.67
- Day Range
- $22.00–22.70
- 52-Week Range
- $12.54–28.91
- Bid/Ask
- $20.00 / $23.72
- Market Cap
- $855.02 Mil
- Volume/Avg
- 118,003 / 410,655
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 29.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 284
Valuation
|
Metric
|
BCYC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.31 |
Price/Sales | 29.92 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BCYC
|
|---|---|
Quick Ratio | 7.92 |
Current Ratio | 8.08 |
Interest Coverage | −58.21 |
Quick Ratio
BCYC
Profitability
|
Metric
|
BCYC
|
|---|---|
Return on Assets (Normalized) | −30.53% |
Return on Equity (Normalized) | −50.74% |
Return on Invested Capital (Normalized) | −46.52% |
Return on Assets
BCYC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cjsgcmhmzw | Pgxn | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jgvvmfkt | Jdssqvs | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vbhnjwg | Lzwfky | $99.5 Bil | |
MRNA
| Moderna Inc | Dhzkgthyf | Mmph | $38.8 Bil | |
ARGX
| argenx SE ADR | Fvffymkb | Qffy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vwhrvvpyw | Tdr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kmwkppvsy | Mxvpd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xlpgmjkqr | Jbspyyy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nndzsbzk | Hbmkbyy | $12.5 Bil | |
INCY
| Incyte Corp | Pznklft | Vxgkgw | $11.6 Bil |